According to a study, although two doses of vaccine of Covid vaccine for people who have received solid organ transplants confer some protection, it is still not enough to enable them to dispense with physical distancing, masks, and other safety measures. To earlier one, this a follow-up study in which the researchers reported that only 17% had developed enough antibodies among participating transplant recipients after just one dose of a two-dose of the Covid.
According to study lead author Brian Boyarsky from the Johns Hopkins University School of Medicine in the U.S, “While there was an increase in those with detectable antibodies after the second shot, the number of transplant recipients in our second study whose antibody levels reached high enough levels to ward off infection was still well below than in people with the healthy immune system.” According to our findings, he further said that transplant recipients and other immunocompromised patients continue to practice strict Covid safety measures, even after vaccination.
The researchers noted that people who receive solid organ transplants, such as kidneys, lungs, and heart, often must take drugs to prevent rejection and suppress their immune systems. A transplant recipient’s ability to make antibodies to foreign substances interferes with such regimens, including the protective ones produced in response to vaccines.
This immunogenic response following the 2nd dose of either of the two mRNA vaccines was evaluated by the latest study, published in the Journal of the American Medical Association for 658 transplant recipients who never had a prior diagnosis of Covid. The participants completed their two-dose regimen between December 16, 2020, and March 13, 2021. The researcher found that out of 658, only 98 had detectable antibodies to Covid at 21 days after the first vaccine dose. After both the vaccines were given out of 658, 301 participants had no detectable antibody at all, while 259 only produced antibodies after the second shot, they said.
The researchers also found that younger was mainly developed an antibody response among the participants who did not take immunosuppressive regimens.